Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Myeloid Leukemia
Research from University of Texas provides new data about acute myeloid leukemia
March 30th, 2008
"Serum 132 microglobulin (beta 2M) is prognostic in other hematologic malignancies; therefore, we evaluated its prognostic significance in acute myeloid leukemia (AML). Multivariate analyses were used to examine the effect of pretreatment serum beta 2M levels on clinical outcomes in patients with AML. beta 2M was associated with poorer survival in older but not younger patients," scientists writing in the journal Clinical Cancer Research report. "We thus fit separate Cox survival models in patients above and below age 60 years treated with remission induction therapy containing high-dose cytarabine (n = 1,280). In each age group, 50% of the patients were used to...
Source: Pharma Investments, Ventures & Law Weekly (2008-03-30)
|
